NIVOPOSTOP (GORTEC 2018-01): A Phase III Trial of Adjuvant Nivolumab in High-Risk Resected Head and Neck Squamous Cell Carcinoma
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NIVOPOSTOP #HNSCC #HeadNeckCancer
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NIVOPOSTOP #HNSCC #HeadNeckCancer
NIVOPOSTOP (GORTEC 2018-01): A Phase III Trial of Adjuvant Nivolumab in High-Risk Resected Head and Neck Squamous Cell Carcinoma - OncoDaily
NIVOPOSTOP trial shows adjuvant nivolumab improves disease-free survival after chemoradiotherapy in high-risk resected head and neck cancer.
oncodaily.com
May 2, 2025 at 9:13 PM
NIVOPOSTOP (GORTEC 2018-01): A Phase III Trial of Adjuvant Nivolumab in High-Risk Resected Head and Neck Squamous Cell Carcinoma
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NIVOPOSTOP #HNSCC #HeadNeckCancer
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NIVOPOSTOP #HNSCC #HeadNeckCancer
Second up! Dr. Jean Bourhis Sr presents NIVOPOSTOP (GORTEC 2018-01): chemoRT +/- nivolumab for resected, high risk head and neck squamous cell carcinoma. 24% risk reduction in disease progression or death: 3-year DFS 63.1 vs 52.5 months (HR 0.76) with substantial drop in locoregional relapse #ASCO25
June 1, 2025 at 6:45 PM
Second up! Dr. Jean Bourhis Sr presents NIVOPOSTOP (GORTEC 2018-01): chemoRT +/- nivolumab for resected, high risk head and neck squamous cell carcinoma. 24% risk reduction in disease progression or death: 3-year DFS 63.1 vs 52.5 months (HR 0.76) with substantial drop in locoregional relapse #ASCO25
This is a fascinating trial
Same survival chemo-SABR 42.3 months vs SABR-alone 41.1 months in #hncsm patients with oligomets
GORTEC 2014-04 “OMET” Randomized Phase 2 Trial in Head and Neck Cancer Patients with Oligometastases using SABR-alone or chemotherapy-SABR
👉 www.redjournal.org/article/S036...
Same survival chemo-SABR 42.3 months vs SABR-alone 41.1 months in #hncsm patients with oligomets
GORTEC 2014-04 “OMET” Randomized Phase 2 Trial in Head and Neck Cancer Patients with Oligometastases using SABR-alone or chemotherapy-SABR
👉 www.redjournal.org/article/S036...
DEFINE_ME
www.redjournal.org
November 30, 2024 at 12:58 AM
This is a fascinating trial
Same survival chemo-SABR 42.3 months vs SABR-alone 41.1 months in #hncsm patients with oligomets
GORTEC 2014-04 “OMET” Randomized Phase 2 Trial in Head and Neck Cancer Patients with Oligometastases using SABR-alone or chemotherapy-SABR
👉 www.redjournal.org/article/S036...
Same survival chemo-SABR 42.3 months vs SABR-alone 41.1 months in #hncsm patients with oligomets
GORTEC 2014-04 “OMET” Randomized Phase 2 Trial in Head and Neck Cancer Patients with Oligometastases using SABR-alone or chemotherapy-SABR
👉 www.redjournal.org/article/S036...
NIVOPOSTOP (GORTEC 2018-01): Ph3 RCT of adjuvant nivolumab added to radio-chemotherapy in Pts w/ resected head & neck squamous cell carcinoma at high risk of relapse - Bourhis et al. #ASCO25 LBA2 meetings.asco.org/abstracts-pr... #NCT03576417 #hncsm #ImmunoOnc
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
April 23, 2025 at 7:20 PM
NIVOPOSTOP (GORTEC 2018-01): Ph3 RCT of adjuvant nivolumab added to radio-chemotherapy in Pts w/ resected head & neck squamous cell carcinoma at high risk of relapse - Bourhis et al. #ASCO25 LBA2 meetings.asco.org/abstracts-pr... #NCT03576417 #hncsm #ImmunoOnc
Nivolumab Improves DFS in High-Risk Head & Neck SCC
The Phase 3 NIVOPOSTOP trial (680 patients) showed that adding nivolumab to standard post-op CRT significantly improved DFS in resected LA-SCCHN with high relapse risk. A trend toward better OS was observed, pending final analysis.
GORTEC Announces New Trial Success for Head and Neck Cancer Treatment
/PRNewswire/ -- GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating...
www.prnewswire.com
January 10, 2025 at 2:20 PM
Nivolumab Improves DFS in High-Risk Head & Neck SCC
The Phase 3 NIVOPOSTOP trial (680 patients) showed that adding nivolumab to standard post-op CRT significantly improved DFS in resected LA-SCCHN with high relapse risk. A trend toward better OS was observed, pending final analysis.
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial. www.thelancet.com/journals/lan...
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-...
Nivolumab added to cisplatin and radiotherapy in high-risk resected LA-SCCHN improves
disease-free survival with moderate toxic effect increase, and can be proposed as
a new standard treatment.
www.thelancet.com
January 8, 2026 at 2:19 PM
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial. www.thelancet.com/journals/lan...
Nivolumab (@bms-news.bsky.social) demonstrates superiority over standard of care for head-and-neck cancer in phase III trial (GORTEC).
https://cancerletter.com/clinical-roundup/20250117_8c/
https://cancerletter.com/clinical-roundup/20250117_8c/
Nivolumab demonstrates superiority over standard of care for head-and-neck cancer in phase III trial - The Cancer Letter
The Groupe d’Oncologie Radiothérapie Tête Et Cou, also known as the Head and Neck Oncology and Radiotherapy Group or GORTEC, announced that the randomized phase III CheckMate -9KW/NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab (Opdivo) as a post-operative treatment component for resected patients with locally advanced squamous cell carcinoma of head and neck with high risk […]
cancerletter.com
January 22, 2025 at 8:46 PM
Nivolumab (@bms-news.bsky.social) demonstrates superiority over standard of care for head-and-neck cancer in phase III trial (GORTEC).
https://cancerletter.com/clinical-roundup/20250117_8c/
https://cancerletter.com/clinical-roundup/20250117_8c/
Le GORTEC Achieves Landmark Success in Head and Neck Cancer Treatment Trial#France#Cancer_Treatment#GORTEC#Nivolumab#Tours
Le GORTEC Achieves Landmark Success in Head and Neck Cancer Treatment Trial
Le GORTEC announces groundbreaking results from the NIVO POST OP trial, showing enhanced disease-free survival for advanced head and neck cancer patients treated with nivolumab.
third-news.com
January 10, 2025 at 4:15 PM
Le GORTEC Achieves Landmark Success in Head and Neck Cancer Treatment Trial#France#Cancer_Treatment#GORTEC#Nivolumab#Tours
GORTEC Announces Landmark Success in Phase 3 Study for Head and Neck Cancer#France#GORTEC#Nivolumab#Head_and_Neck_Cancer#Tours
GORTEC Announces Landmark Success in Phase 3 Study for Head and Neck Cancer
GORTEC has declared significant results from the NIVOPOSTOP GORTEC 2018-01 study, showing Nivolumab's effectiveness in enhancing disease-free survival for high-risk head and neck cancer patients.
third-news.com
January 7, 2025 at 7:11 PM
GORTEC Announces Landmark Success in Phase 3 Study for Head and Neck Cancer#France#GORTEC#Nivolumab#Head_and_Neck_Cancer#Tours
GORTEC's Phase 3 Trial Shows Promising Results for Head and Neck Cancer Treatment#USA#GORTEC#Nivolumab#Head_and_Neck_Cancer#Tours
GORTEC's Phase 3 Trial Shows Promising Results for Head and Neck Cancer Treatment
GORTEC announces significant findings from their Phase 3 trial on nivolumab for head and neck cancer, marking a breakthrough in treatment options.
third-news.com
January 7, 2025 at 1:16 PM
GORTEC's Phase 3 Trial Shows Promising Results for Head and Neck Cancer Treatment#USA#GORTEC#Nivolumab#Head_and_Neck_Cancer#Tours
GORTEC's Phase 3 Trial Demonstrates Breakthrough in Head and Neck Cancer Treatment#France#GORTEC#Nivolumab#Head_and_Neck_Cancer#Tours
GORTEC's Phase 3 Trial Demonstrates Breakthrough in Head and Neck Cancer Treatment
GORTEC has announced successful results from its Phase 3 trial, NIVOPOSTOP GORTEC 2018-01, showcasing improved outcomes for head and neck cancer patients.
third-news.com
January 7, 2025 at 1:12 PM
GORTEC's Phase 3 Trial Demonstrates Breakthrough in Head and Neck Cancer Treatment#France#GORTEC#Nivolumab#Head_and_Neck_Cancer#Tours
